Mechanisms of Alcohol Tolerance (R21/R33 Clinical Trial Optional) | PAR 21 250

FAQs: Mechanisms of Alcohol Tolerance (R21/R33 Clinical Trial Optional) - PAR-21-250

What is this funding opportunity?

This is an NIH discretionary grant opportunity titled "The Mechanisms of Alcohol Tolerance (R21/R33 Clinical Trial Optional)" with Funding Opportunity Number PAR-21-250. It sits in the health area under CFDA 93.273 and is overseen by the National Institute on Alcohol Abuse and Alcoholism (NIAAA).

What is the main purpose of PAR-21-250?

The opportunity is focused on the biological and computational foundations of alcohol sensitivity and tolerance as they relate to the development of alcohol use disorder (AUD). The central goal is to push research beyond descriptive findings and toward clear, testable mechanistic explanations for how tolerance arises, how it is regulated, how it changes over time, and how it may increase risk for AUD.

What kinds of research questions is the FOA trying to drive?

The FOA emphasizes "mechanism plus prediction." In practice, that means proposing concrete, evidence-driven hypotheses about what changes with repeated alcohol exposure (biologically and/or in neural systems), how those changes unfold, and whether the resulting changes can be used to forecast tolerance development and trajectories toward AUD.

What are the two main scientific aims highlighted in the announcement?

The FOA highlights two main aims: (1) develop hypotheses about cellular, molecular, or network-level mechanisms controlling alcohol sensitivity and tolerance; and (2) develop quantitative models that can predict tolerance development and progression toward AUD.

What does "mechanisms of alcohol sensitivity and tolerance" mean in this context?

In this FOA, mechanism-focused projects are expected to explain how tolerance and sensitivity are regulated at a biological or systems level. The announcement points to possible mechanistic areas such as signaling pathways, receptor and ion channel adaptations, synaptic and circuit changes, gene expression and epigenetic regulation, glial and neuroimmune contributions, and broader neural network dynamics that shift with repeated alcohol exposure.

What kinds of quantitative or computational modeling are encouraged?

The FOA invites modeling approaches that can transform biological and behavioral data into predictive frameworks for tolerance and AUD risk. Examples mentioned include computational neuroscience models, statistical or machine learning models, dynamical systems models, and multiscale models linking molecular changes to circuit function and behavior.

Is this opportunity only for computational projects?

No. The FOA supports projects that uncover mechanisms and/or build predictive quantitative models. Applicants can propose preclinical, translational, computational, or human-focused research, as long as the project is tightly aligned with the goals of explaining mechanisms of tolerance/sensitivity and developing models related to tolerance and AUD progression.

What grant mechanism is being used?

This opportunity uses the NIH R21/R33 Phased Innovation Award mechanism. The structure is designed to support early, high-impact work that can mature into a larger, more expansive research program if prespecified milestones are met.

What is the purpose of the R21 phase?

The R21 phase is intended for secondary data analysis and/or pilot studies. Its role is to de-risk the concept, refine measures, establish feasibility, and generate preliminary evidence that supports the mechanistic hypotheses and/or model development planned for later testing.

What is the purpose of the R33 phase?

The R33 phase is where the project scales up to more fully test the hypotheses and models developed in the R21 phase. This may involve stronger designs, larger datasets, or more comprehensive experimental and analytic work intended to rigorously evaluate the proposed mechanisms and predictive models.

Does an award automatically move from R21 to R33?

No. Transition from R21 to R33 is not automatic. NIAAA program staff evaluate whether R21 milestones were achieved and decide on the transition based on the predefined benchmarks included in the application.

What are "R21 milestones" and why do they matter?

R21 milestones are clear, measurable benchmarks that the project must hit during the R21 phase to justify moving into the R33 phase. Because the transition is milestone-driven, competitive applications typically include explicit go/no-go criteria that logically connect the R21 work to the larger R33 plan.

What does "Clinical Trial Optional" mean for this FOA?

"Clinical Trial Optional" means applicants may propose projects that include a clinical trial or projects that do not, depending on the scientific question and approach. The key requirement is alignment with the FOA's focus on mechanisms of tolerance/sensitivity and quantitative modeling relevant to tolerance and AUD progression.

Can this FOA support secondary data analysis?

Yes. The R21 phase explicitly allows for secondary data analysis and/or pilot studies. This makes the opportunity relevant to teams with access to existing datasets who want to generate mechanistic hypotheses and develop model prototypes before expanding into more comprehensive work.

What types of organizations are eligible to apply?

Eligibility is broad. Eligible applicants include state, county, city or township governments; special district governments; independent school districts; public housing or Indian housing authorities; public and state-controlled institutions of higher education; private institutions of higher education; nonprofits with or without 501(c)(3) status; for-profit organizations (other than small businesses); and small businesses.

Are Tribal and other community-centered organizations included in eligibility?

Yes. The FOA explicitly welcomes Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, Historically Black Colleges and Universities, Tribal governments (federally recognized and other than federally recognized), Tribal colleges and universities (including TCCUs), and faith-based or community-based organizations.

Are non-U.S. organizations eligible?

Yes. Non-U.S. (foreign) organizations are listed among eligible applicants. The eligibility list also includes U.S. territories or possessions and regional organizations, as well as eligible federal agencies.

Which NIH institute is responsible for programmatic oversight?

NIH is the sponsoring agency, and NIAAA oversees programmatic decisions for this opportunity, including decisions related to the R21-to-R33 transition based on milestone achievement.

What is the CFDA number associated with this opportunity?

The CFDA listing provided for this opportunity is 93.273.

What are the key dates provided for this FOA?

The FOA was created on 2021-06-22. The original closing date listed is 2024-09-07.

Is the award ceiling or the expected number of awards provided?

Not in the provided listing. The information given does not specify an award ceiling or the expected number of awards. Applicants are typically expected to consult the full FOA details and NIH budget guidance for the mechanism to understand allowable costs and project period structure.

What types of projects does the FOA seem best suited for?

Based on the description provided, the FOA is best suited for projects that credibly connect mechanistic biology and/or neural circuitry with rigorous quantitative modeling to explain and predict alcohol tolerance and AUD risk, using a staged plan where R21 work produces the evidence and milestones needed to justify a larger R33 expansion.